Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma

The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is:

· Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet > 100*10^9/L.

Inclusion Criteria:

• Age<18 years old;
• Diagnosed as neuroblastoma;
• ECOG ≤ 2;
• First time receiving autologous hematopoietic stem cell transplantation;
• The subjects or their legal guardians agree to participate and sign the informed consent form.

Exclusion Criteria:

• ALT/AST > 3 ULN, or TBIL > 1.5 ULN;
• Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment;
• Suffering from thromboembolic diseases;
• Other situations that are not suitable for inclusion in the study determined by researchers.